Literature DB >> 3596960

Leukotriene D4 and indomethacin enhance additively the macrophage cytostatic activity in vitro towards MOPC-315 tumour cells.

R Ophir, S Ben-Efraim, I L Bonta.   

Abstract

Leukotriene C4, the precursor of leukotriene D4 (LTD4), was earlier shown to activate macrophages, as indicated by lysosomal enzyme discharge. This event is limited by LT-induced secretion of PGE2, which inhibits the functions of these cells. The circumstance that activated macrophages may exert cytostatic activity towards tumour cells prompted us to study the effect of LTD4 and indomethacin on the cytostatic activity of macrophages as expressed by inhibition of [3H]thymidine incorporation in MOPC-315 plasmacytoma tumour cells. Decrease in incorporation, caused by separate administration of the two substances, was additively enhanced upon exposure of the co-culture of macrophages and tumour cells to the two substances simultaneously. Tumour cells alone are not affected by the substances, but the low rate of thymidine incorporation by macrophages alone was increased by LTD4 in the presence of indomethacin. Decrease of thymidine incorporation into tumour cells co-cultured with macrophages is attributed to a macrophage-mediated, rather than to a direct, influence of LTD4 and indomethacin on tumour cells. An increase in macrophage-mediated cytostasis by LTD4 requires the inhibition of endogenous PGE2 production in macrophages.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3596960

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  9 in total

1.  Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is enhanced by endogenous metabolites of lipoxygenase and counteracted by prostaglandin E2.

Authors:  I L Bonta; G R Elliott; C Tak; S Ben-Efraim
Journal:  Agents Actions       Date:  1989-01

2.  Prostaglandin E2 enhances, and leukotriene C4 inhibits, interleukin-1 inhibition of WEHI-3B cell growth.

Authors:  G R Elliott; C Tak; I L Bonta
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Indomethacin stimulation of macrophage cytostasis against MOPC-315 tumor cells is inhibited by both prostaglandin E2 and nordihydroguaiaretic acid, a lipoxygenase inhibitor.

Authors:  G R Elliott; C Tak; C Pellens; S Ben-Efraim; I L Bonta
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Leukotrienes and macrophage activation: augmented cytotoxic activity and enhanced interleukin 1, tumor necrosis factor and hydrogen peroxide production.

Authors:  L Gagnon; L G Filion; C Dubois; M Rola-Pleszczynski
Journal:  Agents Actions       Date:  1989-01

5.  Influence of zymosan (a non-specific macrophage stimulator) and of indomethacin on liver tumours--an experimental study in rats.

Authors:  S B Holmberg; P L Naredi; G O Lindnér; I H Karlberg; P L Daneryd; L M Karlsson; A Pettersson; U Stenram; L R Hafström
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

6.  Inflammation amplifies the antitumor cytostasis by human peritoneal macrophages.

Authors:  S Ben-Efraim; C Tak; M J Fieren; G J Van den Bemd; I L Bonta
Journal:  Med Oncol Tumor Pharmacother       Date:  1991

7.  Interactions between rnacrophage cytokines and eicosanoids in expression of antitumour activity.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

8.  Cancer immunotherapy: potential involvement of mediators.

Authors:  S Ben-Efraim
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

9.  Opposing effects of indomethacin and nordihydroguaiaretic acid on macrophage function and tumor growth.

Authors:  M Suzuki; J Li; T Asakura; K Arai
Journal:  Jpn J Cancer Res       Date:  1994-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.